Richardson, P. G., Soiffer, R., Antin, J. H., Vredenburgh, J., Kurtzberg, J., Martin, P. L., … Guinan, E. C. (2002). Defibrotide (DF) appears effective and safe in a phase II, randomized study of patients (pts) with severe veno-occlusive disease (VOD) and multi-system organ failure (MOF) post stem cell transplantation (SCT). In BLOOD (Vol. 100, pp. 112A-112A). PHILADELPHIA, PENNSYLVANIA: AMER SOC HEMATOLOGY.

Richardson, P. G., R. Soiffer, J. H. Antin, J. Vredenburgh, J. Kurtzberg, P. L. Martin, D. Hockenbery, et al. “Defibrotide (DF) appears effective and safe in a phase II, randomized study of patients (pts) with severe veno-occlusive disease (VOD) and multi-system organ failure (MOF) post stem cell transplantation (SCT).” In BLOOD, 100:112A-112A. AMER SOC HEMATOLOGY, 2002.

Richardson PG, Soiffer R, Antin JH, Vredenburgh J, Kurtzberg J, Martin PL, et al. Defibrotide (DF) appears effective and safe in a phase II, randomized study of patients (pts) with severe veno-occlusive disease (VOD) and multi-system organ failure (MOF) post stem cell transplantation (SCT). In: BLOOD. AMER SOC HEMATOLOGY; 2002. p. 112A-112A.

Richardson, P. G., et al. “Defibrotide (DF) appears effective and safe in a phase II, randomized study of patients (pts) with severe veno-occlusive disease (VOD) and multi-system organ failure (MOF) post stem cell transplantation (SCT).” BLOOD, vol. 100, no. 11, AMER SOC HEMATOLOGY, 2002, pp. 112A-112A.

Richardson PG, Soiffer R, Antin JH, Vredenburgh J, Kurtzberg J, Martin PL, Hockenbery D, Steinbach G, Murray K, Vogelsang G, Chen A, Warren DL, Momtaz P, Wei LJ, Jin Z, Rifai N, Bradwin G, Iacobelli M, McDonald GB, Guinan EC. Defibrotide (DF) appears effective and safe in a phase II, randomized study of patients (pts) with severe veno-occlusive disease (VOD) and multi-system organ failure (MOF) post stem cell transplantation (SCT). BLOOD. AMER SOC HEMATOLOGY; 2002. p. 112A-112A.